Soligenix Successfully Completes U.S. Manufacturing Transfer of Synthetic Hypericin with Sterling Pharma Solutions

Stock Information for Soligenix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Soligenix Inc.

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer
Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.